Actavis' generic Inderal LA gets US approval

Iceland-based generic drug major Actavis has received approval from the US Food and Drug Administration to market propranolol HCl extended-release capsules. Distribution of the product will commence immediately.

The Actavis product is the generic equivalent of Wyeth Pharmaceuticals' Inderal LA capsules and available in 60mg, 80mg, 120mg and 160mg dosage strengths. Propranolol ER capsules are indicated for the treatment of high blood pressure, long-term management of angina pectoris and prophylaxis of common migraine headaches.

Doug Boothe, executive vice president of US commercial and administration at Actavis said: "the launch of propranolol is an important milestone for Actavis. With one of the strongest product pipelines in the industry, we continue to grow our business by increasing our product offering with affordable high quality generic drugs. This launch is also in line with our strategy to further grow our business in the controlled release product market and exemplifies our capability in controlled release oral solid products."